Conjunctivitis Market Size is Forecasted to Reach US$ 6.31 Billion by 2030

According to Precedence Research, the conjunctivitis market size is forecasted to reach around US$ 6.31 billion by 2030, growing at a 3.65% CAGR from 2021 to 2030.

Conjunctivitis is a contamination of the conjunctiva, a slim membrane layering the white portion of the sclera, eye, or the internal surface of the lids. Conjunctivitis can be very contagious and expand easily within large collections of people. Occasionally, especially in children, the ailment can affect visualization. In such situations, clinicians need to be knowledgeable immediately for effective and primary treatment.

Causes of Conjunctivitis:

• Bacteria
• Virus
• Allergens
• Irritant such as Chemicals

Download Free Sample Copy with TOC, Graphs & List of Figures @ https://www.precedenceresearch.com/sample/1230

Type of conjunctivitis:

Based on the different agents leading to conjunctivitis, the condition can be classified into the following types.

Bacterial Conjunctivitis:

When the eye’s ability to resist bacterial infections is compromised, conjunctival infection occurs. This can happen during serious illnesses or in immunocompromised individuals. Bacteria such as Streptococcus pneumoniae, the Moraxella species, the Hemophilus species, and the Staphylococcus species can lead to infection. Bacterial conjunctivitis can be further classified into the following types.

Viral Conjunctivitis:

Viral conjunctivitis is caused by viruses and is found to be associated with upper respiratory tract infections. It is a highly contagious condition that begins in one eye and often spreads to the other. As antibiotics do not cure this type of infection, infected individuals must wait for the condition to ease by itself. Medical attention is essential if the infection lasts for over seven days. Adenoviruses and herpes viruses are commonly associated with viral conjunctivitis.

Allergic conjunctivitis:

The conjunctiva, when exposed to the environment, is often associated with allergic and immune-mediated reactions, which lead to allergic conjunctivitis. In this condition, type 1 hypersensitivity reactions occur when an allergen reacts with IgE antibodies, resulting in mast cell degranulation and release of inflammatory mediators. Allergic conjunctivitis can be further classified into the following types.

Report Scope of the Conjunctivitis Market

COVID-19 Impact:

The industrial report mentions the influence of the ongoing COVID-19 pandemic. The outbreak has caused disturbances in several industries and has hammered the logistics, resulting in delayed deliveries and cancellation of product demand. The conjunctivitis report proficiently explains the resulting factors and concerns of manufacturers. Researchers have also well-explained how the producers and providers will tackle the ongoing epidemic and the key strategies to be adopted post-pandemic for turning their businesses back to normal.

Growth Factors:

Factors such as increasing prevalence of conjunctivitis, increasing healthcare expenditure, rising exposure to allergens, highly contagious nature of conjunctivitis are driving the growth of conjunctivitis market. Moreover, Additional features that are expected to fuel this business are integration of latest technologies and growing investment by major players.

Smoking affects the ocular surface, resulting in redness, itchiness, and irritation of the eyes. This can cause atopic keratoconjunctivitis and allergic conjunctivitis due to decreased conjunctival sensitivity. Industrialization, especially the automobile industry, involves high levels of pollutants and chemicals. Exposure to diesel exhausts increases the density of inflammatory cells, such as IL-6 and intercellular adhesion molecule-1, leading to the development of allergic conjunctivitis. This will drive the growth of the conjunctivitis medication market, as more individuals will require treatment.

Report Highlights:

• Among the type segment, allergic conjunctivitis dominated the overall market in 2020. High prevalence of allergic conjunctivitis due to high exposure to allergen is the foremost factors attributing to its large market share.
• The adults segment accounted for the major share of revenue in the patient type segment with more than 63% share in 2020 due to high incidence of conjunctivitis in adults. Pediatric segment is anticipated to grow at the uppermost CAGR through the forecast duration.
• Anti-histaminic accounted for the largest revenue in the drug-class segment. Use of anti-histaminic for the management of allergic conjunctivitis is the key reason for high market share. Steroid Drugs segment is expected to grow at the highest growth rate through the estimate duration.
• Allegran, Pfizer Inc, Atopix Therapeutics Ltd. accounted for a significant share of the global conjunctivitis market.

Regional Analysis:

The report includes information for Asia Pacific, North America, Latin America, Europe, Middle East, and Africa. In 2020, the North America region dominated the worldwide market with a market share of higher than 43%. The U.S. indicated the highest slice in North America principally due to early application of latest technologies. Moreover, availability of latest healthcare infrastructure also supported the high market portion of North America.

Europe was the subsequent significant market chiefly due to presence of skilled physicians. Presence of major companies in the European region is also expected to lift the demand for conjunctivitis in the anticipated time-span. The Asia Pacific region is projected to grow at the highest CAGR of around 5.35% in the estimate period due to increasing healthcare expenditure. Latin America and Middle East and African region will display noticeable growth.

Key Players:

The conjunctivitis market is consolidated with a major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the prominent players in the conjunctivitis market include:

• Atopix Therapeutics Ltd.
• Allegran
• Ocular Therapeutix, Inc.
• Santen Pharmaceutical Co. Ltd.
• Novartis
• Boehringer Ingelheim
• Pfizer Inc
• Allegran
• Sun Pharma
• Sirion Therapeutics, Inc.

Market Segmentation

By Type

• Bacterial Conjunctivitis
• Viral Conjunctivitis
• Allergic Conjunctivitis

By Patients Type

• Pediatric
• Adults

By Drug Class

• Antibiotics
• Anti-Histaminic
• Decongestant
• Steroid Drugs
• Others

Regional Segmentation

• North America (U.S. and Canada)
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
• Latin America (Brazil and Rest of Latin America)
• Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Conjunctivitis Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Conjunctivitis Market

5.1. Covid-19: Conjunctivitis Industry Impact
5.2. Conjunctivitis Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Conjunctivitis Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Conjunctivitis Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Conjunctivitis Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increased exposure to chemicals and pollutants
6.1.1.2. Rising awareness of condition
6.1.2. Market Restraints
6.1.2.1. Lack of Self Awareness
6.1.3. Market Opportunities
6.1.3.1. Exploring specific treatment for viral conjunctivitis

Chapter 7. Global Conjunctivitis Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Conjunctivitis Market Revenue by Market Players (2016 -2019)
7.1.1.2. Conjunctivitis Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Conjunctivitis Market, By Type

8.1. Conjunctivitis Market, by Type, 2017-2030
8.1.1. Bacterial Conjunctivitis
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Viral Conjunctivitis
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Allergic Conjunctivitis
8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Conjunctivitis Market, By Patients Type

9.1. Conjunctivitis Market, by Application, 2017-2030
9.1.1. Pediatric
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Adults
9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Conjunctivitis Market, By Drug Class

10.1. Conjunctivitis Market, by Application, 2017-2030
10.1.1. Antibiotics
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Anti-Histaminic
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Decongestant
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Steroid Drugs
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Conjunctivitis Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Type(2017-2030)
11.1.2. Market Revenue Forecast by Patients Type (2017-2030)
11.1.3. Market Revenue Forecast by Drug Class (2017-2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017-2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017-2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Type (2017-2030)
11.2.2. Market Revenue Forecast by Patients Type (2017-2030)
11.2.3. Market Revenue Forecast by Drug Class (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017-2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017-2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Type (2017-2030)
11.3.2. Market Revenue Forecast by Patients Type (2017-2030)
11.3.3. Market Revenue Forecast by Drug Class (2017-2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017-2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Type (2017-2030)
11.4.2. Market Revenue Forecast by Patients Type (2017-2030)
11.4.3. Market Revenue Forecast by Drug Class (2017-2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017-2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017-2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Type (2017-2030)
11.5.2. Market Revenue Forecast by Patients Type (2017-2030)
11.5.3. Market Revenue Forecast by Drug Class (2017-2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017-2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017-2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017-2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017-2030)

Chapter 12. Company Profiles

12.1. Atopix Therapeutics Ltd.
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Type Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.1.4. Recent Developments and Strategies
12.2. Allegran
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Type Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.2.4. Recent Developments and Strategies
12.3. Ocular Therapeutix, Inc.
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Type Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.3.4. Recent Developments and Strategies
12.4. Santen Pharmaceutical Co. Ltd.
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Type Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.4.4. Recent Developments and Strategies
12.5. Novartis
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Type Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.5.4. Recent Developments and Strategies
12.6. Boehringer Ingelheim
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Type Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.6.4. Recent Developments and Strategies
12.7. Boehringer Ingelheim
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Type Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.7.4. Recent Developments and Strategies
12.8. Sun Pharma
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Type Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.8.4. Recent Developments and Strategies
12.9. Sirion Therapeutics, Inc.
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Type Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.9.4. Recent Developments and Strategies
12.10. Company 10
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Type Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin (2016 – 2019)
12.10.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1230

Contact Us:         

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com